Published in
Oxford University Press, Open Forum Infectious Diseases, 11(7), 2020
DOI: 10.1093/ofid/ofaa528
Links
Tools
COVID-19 investigational treatments in use among hospitalized patients identified through the U.S. Coronavirus Disease 2019 -Associated Hospitalization Surveillance Network, March 1–June 30, 2020
Journal article published in 2020 by
Anna M. Acosta 
,
Adria L. Mathis,
Daniel S. Budnitz,
Andrew I. Geller,
Shua J. Chai,
Nisha B. Alden,
James Meek,
Evan J. Anderson ,
Patricia Ryan,
Sue Kim,
Kathryn Como-Sabetti,
Salina Torres,
Elizabeth Dufort,
Nancy M. Bennett,
Laurie M. Billing
and other authors.
,
Adria L. Mathis,
Daniel S. Budnitz,
Andrew I. Geller,
Shua J. Chai,
Nisha B. Alden,
James Meek,
Evan J. Anderson ,
Patricia Ryan,
Sue Kim,
Kathryn Como-Sabetti,
Salina Torres,
Elizabeth Dufort,
Nancy M. Bennett,
Laurie M. Billing
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Abstract Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.